Does aldosterone predict incident cardiovascular, renal, and metabolic disease in the general community?
Aldosterone levels predict the development of cardiometabolic and renal diseases, including hypertension, diabetes, and CKD, over a 4-year period in the general community.
Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.
Buglioni et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: